Uniqure NVNASDAQ:QURE
- LAST PRICE4.4800
- TODAY'S CHANGE (%)-0.0600 (-1.3216%)
- Bid / Lots4.3000/ 6
- Ask / Lots4.5500/ 10
- Open / Previous Close4.5000 / 4.5400
- Day Range
- 52 Week Range
- Volume435,444
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QURE |
|---|---|---|
| 09:32 ET | 5228 | 4.5425 |
| 09:34 ET | 200 | 4.56 |
| 09:38 ET | 1348 | 4.57 |
| 09:43 ET | 409 | 4.5441 |
| 09:45 ET | 100 | 4.555 |
| 09:50 ET | 1099 | 4.44 |
| 09:54 ET | 626 | 4.45 |
| 09:56 ET | 600 | 4.47 |
| 09:57 ET | 5008 | 4.45 |
| 09:59 ET | 10234 | 4.39 |
| 10:01 ET | 1512 | 4.42 |
| 10:03 ET | 400 | 4.41 |
| 10:06 ET | 1900 | 4.42 |
| 10:08 ET | 11044 | 4.415 |
| 10:10 ET | 208 | 4.42 |
| 10:12 ET | 440 | 4.44 |
| 10:15 ET | 100 | 4.44 |
| 10:17 ET | 931 | 4.44 |
| 10:19 ET | 100 | 4.42 |
| 10:24 ET | 434 | 4.415 |
| 10:26 ET | 1900 | 4.43 |
| 10:30 ET | 210 | 4.435 |
| 10:32 ET | 827 | 4.456 |
| 10:33 ET | 1746 | 4.4372 |
| 10:35 ET | 2241 | 4.43 |
| 10:37 ET | 400 | 4.43 |
| 10:42 ET | 1292 | 4.42 |
| 10:44 ET | 325 | 4.41 |
| 10:46 ET | 2205 | 4.415 |
| 10:48 ET | 300 | 4.42 |
| 10:50 ET | 250 | 4.425 |
| 10:51 ET | 265 | 4.42 |
| 10:53 ET | 11156 | 4.41 |
| 10:57 ET | 400 | 4.3803 |
| 11:00 ET | 200 | 4.385 |
| 11:02 ET | 2032 | 4.395 |
| 11:04 ET | 1631 | 4.41 |
| 11:06 ET | 200 | 4.41 |
| 11:09 ET | 6897 | 4.424 |
| 11:11 ET | 4438 | 4.4499 |
| 11:15 ET | 4165 | 4.425 |
| 11:18 ET | 620 | 4.405 |
| 11:20 ET | 200 | 4.405 |
| 11:22 ET | 200 | 4.405 |
| 11:24 ET | 895 | 4.405 |
| 11:26 ET | 5407 | 4.405 |
| 11:27 ET | 896 | 4.41 |
| 11:31 ET | 1131 | 4.405 |
| 11:36 ET | 2437 | 4.395 |
| 11:40 ET | 100 | 4.395 |
| 11:42 ET | 266 | 4.39 |
| 11:44 ET | 400 | 4.385 |
| 11:47 ET | 100 | 4.385 |
| 11:49 ET | 2004 | 4.37 |
| 11:51 ET | 715 | 4.38 |
| 11:54 ET | 303 | 4.38 |
| 11:56 ET | 3159 | 4.38 |
| 11:58 ET | 802 | 4.39 |
| 12:00 ET | 100 | 4.4 |
| 12:02 ET | 600 | 4.4 |
| 12:03 ET | 500 | 4.41 |
| 12:07 ET | 431 | 4.4 |
| 12:09 ET | 400 | 4.39 |
| 12:12 ET | 443 | 4.385 |
| 12:14 ET | 100 | 4.38 |
| 12:16 ET | 100 | 4.38 |
| 12:21 ET | 100 | 4.375 |
| 12:23 ET | 4700 | 4.3762 |
| 12:25 ET | 15200 | 4.365 |
| 12:27 ET | 1200 | 4.375 |
| 12:30 ET | 257 | 4.38 |
| 12:32 ET | 703 | 4.38 |
| 12:34 ET | 100 | 4.385 |
| 12:36 ET | 100 | 4.38 |
| 12:38 ET | 200 | 4.38 |
| 12:39 ET | 1831 | 4.3797 |
| 12:43 ET | 2000 | 4.37 |
| 12:45 ET | 1680 | 4.375 |
| 12:48 ET | 1916 | 4.36 |
| 12:50 ET | 100 | 4.365 |
| 12:54 ET | 6684 | 4.385 |
| 12:56 ET | 500 | 4.38 |
| 12:57 ET | 220 | 4.39 |
| 01:01 ET | 231 | 4.38 |
| 01:03 ET | 200 | 4.375 |
| 01:08 ET | 400 | 4.375 |
| 01:10 ET | 1404 | 4.38 |
| 01:14 ET | 1462 | 4.355 |
| 01:15 ET | 100 | 4.36 |
| 01:17 ET | 200 | 4.355 |
| 01:19 ET | 856 | 4.36 |
| 01:24 ET | 100 | 4.365 |
| 01:26 ET | 350 | 4.36 |
| 01:28 ET | 300 | 4.355 |
| 01:30 ET | 1603 | 4.35 |
| 01:32 ET | 812 | 4.335 |
| 01:33 ET | 983 | 4.34 |
| 01:35 ET | 600 | 4.3299 |
| 01:37 ET | 2436 | 4.31 |
| 01:39 ET | 200 | 4.315 |
| 01:42 ET | 100 | 4.31 |
| 01:44 ET | 700 | 4.315 |
| 01:46 ET | 1165 | 4.32 |
| 01:48 ET | 9200 | 4.315 |
| 01:50 ET | 4012 | 4.34 |
| 01:51 ET | 208 | 4.35 |
| 01:53 ET | 1385 | 4.33 |
| 01:55 ET | 131 | 4.32 |
| 01:57 ET | 116 | 4.33 |
| 02:00 ET | 100 | 4.325 |
| 02:02 ET | 4366 | 4.3198 |
| 02:04 ET | 600 | 4.315 |
| 02:06 ET | 299 | 4.319 |
| 02:08 ET | 800 | 4.325 |
| 02:09 ET | 1253 | 4.34 |
| 02:13 ET | 298 | 4.35 |
| 02:15 ET | 200 | 4.35 |
| 02:18 ET | 400 | 4.35 |
| 02:22 ET | 300 | 4.355 |
| 02:24 ET | 200 | 4.35 |
| 02:27 ET | 100 | 4.35 |
| 02:29 ET | 2318 | 4.39 |
| 02:33 ET | 1155 | 4.3787 |
| 02:38 ET | 200 | 4.38 |
| 02:44 ET | 100 | 4.39 |
| 02:45 ET | 545 | 4.39 |
| 02:47 ET | 6375 | 4.405 |
| 02:49 ET | 600 | 4.405 |
| 02:54 ET | 100 | 4.405 |
| 02:56 ET | 100 | 4.405 |
| 02:58 ET | 200 | 4.4 |
| 03:00 ET | 300 | 4.39 |
| 03:02 ET | 2200 | 4.37 |
| 03:03 ET | 100 | 4.38 |
| 03:07 ET | 100 | 4.38 |
| 03:12 ET | 100 | 4.37 |
| 03:14 ET | 10178 | 4.37 |
| 03:16 ET | 6373 | 4.37 |
| 03:18 ET | 1000 | 4.3735 |
| 03:20 ET | 9469 | 4.37 |
| 03:21 ET | 200 | 4.3701 |
| 03:23 ET | 16570 | 4.365 |
| 03:25 ET | 3035 | 4.365 |
| 03:27 ET | 600 | 4.36 |
| 03:30 ET | 4220 | 4.375 |
| 03:32 ET | 401 | 4.37 |
| 03:34 ET | 800 | 4.37 |
| 03:36 ET | 100 | 4.375 |
| 03:39 ET | 300 | 4.375 |
| 03:41 ET | 7123 | 4.385 |
| 03:43 ET | 700 | 4.385 |
| 03:45 ET | 1559 | 4.375 |
| 03:48 ET | 7625 | 4.395 |
| 03:50 ET | 1742 | 4.3999 |
| 03:52 ET | 6308 | 4.42 |
| 03:54 ET | 4040 | 4.45 |
| 03:56 ET | 3516 | 4.465 |
| 03:57 ET | 24613 | 4.46 |
| 03:59 ET | 10791 | 4.48 |
Jun 3, 2024
DJ UniQure's AMT-130 Gets FDA RMAT Designation in Huntington's Disease, from 7:39AM ET on Monday Jun 03, 2024 by Dow Jones
7:39AM ET on Monday Jun 03, 2024 by Dow JonesuniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease, from 7:05AM ET on Monday Jun 03, 2024 by Dow Jones
7:05AM ET on Monday Jun 03, 2024 by Dow JonesuniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease, from 7:05AM ET on Monday Jun 03, 2024 by Dow Jones
7:05AM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Uniqure NV | 217.5M | -0.7x | --- |
MeiraGTx Holdings PLC | 270.7M | -3.3x | --- |
Lineage Cell Therapeutics Inc | 188.3M | -7.4x | --- |
TriSalus Life Sciences Inc | 149.9M | -2.6x | --- |
Fennec Pharmaceuticals Inc | 166.9M | 167.1x | --- |
Mediwound Ltd | 144.1M | -11.2x | --- |
Company Information
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Contact Information
- Headquarters
- Paasheuvelweg 25aAMSTERDAM, Netherlands 1105 BP
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- David Meek
- Chief Executive Officer, Executive Director
- Matthew Kapusta
- Chief Financial Officer
- Christian Klemt
- Chief Operations Officer
- Pierre Caloz
- Chief Business and Scientific Officer
- Richard Porter
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $217.5M |
|---|---|
Revenue (TTM) | $19.0M |
Shares Outstanding | 48.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.96 |
EPS | $-6.20 |
Book Value | $4.34 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 11.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,383.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
